Surgical Innovations Share Discussion Threads

[mandate] 15/1/2019 09:34

... or the waters are muddied due to brexit. Not too sure about 'loads of cheap shares' and 'eager sellers' though.

[gbh2] 14/1/2019 17:19

Still loads of cheap shares in the hands of eager sellers imo.

[bashor] 14/1/2019 15:18

Not sure I’ll ever fully understand the markets, why is this being marked down did they want more detail? Still if SUN can generate £1.2m to £1.5m of free cash PA over the next couple of years I’d say they are a bargain at 3p

[bashor] 14/1/2019 10:24

I’d be happy with 5p

[romeike] 14/1/2019 10:19

6p by year end, buy on dips

[bashor] 14/1/2019 08:37

Looks like we have a steady ship, the share price should steadily improve

[lurki0] 14/1/2019 08:06

Very positive update - as we'd all been hoping. Excellent news.

[bjfanc] 14/1/2019 07:46

Back on track, should be closer to 4

[buywell3] 14/1/2019 07:24

.......................... Onwards and Upwards ......... 12.5M next year please .....................


14 January 2019

Surgical Innovations Group plc



Year-end Trading Update

Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of innovative technology for minimally invasive surgery, provides an update on trading for the year ended 31 December 2018.

Trading was significantly stronger in the second half of the year, resulting in Group revenue for the full year of approximately GBP11.0m.

This represents growth of approximately 25% over 2017, with underlying revenue growth (adjusted for the effect of the acquisition of Elemental Healthcare Limited in August 2017) of approximately 8%. Gross margin was within target range and the resulting increase in profit before tax is anticipated to be in line with Board expectations and market consensus.

The Group continued to be cash generative, with closing net cash balances of approximately GBP0.36m, compared with net debt at the start of the year of GBP0.73m.

Audited results for the year ended 31 December 2018 will be released in mid-March 2019.

[buywell3] 13/1/2019 21:19

One of the things that has been brought home to me recently is the perilous state the NHS is in regarding the way the numbers of Hospital Beds have been reduced.



Sep 29, 2017

- The number of NHS hospital beds in England has more than halved over the past 30 years.


So now 50% less NHS Hospital beds than in Sept 1987 ... yet the Government to get elected always bangs on about just how much attention/effort/money it will spend upon it.

But in the last 30 years we have lost 50% of capacity ???? after spending all that money ???

Resulting last year to thousands of planned operations being cancelled

NHS cancels 14% of operations at last minute, research finds


Sep 7, 2018 - One in seven NHS hospital operations are being cancelled just before they are due to take place, often because of a lack of bed


This is the present lamentable situation that the NHS is now in

Record numbers of NHS operations cancelled at last minute

› News

May 10, 2018 - The number of patients who had NHS operations cancelled at the last minute is the highest in almost 25 years, new figures show


What this tells me is that the COST CUTTING within the NHS regarding bed reductions has now gone to a CRISIS point

Then we get to read this every year now regarding the latest Flu going around

NHS hospitals ordered to cancel all routine operations in January as ...
› News

Jan 2, 2018 - NHS hospitals ordered to cancel all routine operations in January as flu spike ... Hospitals are reporting growing chaos, with a spike in winter flu


You don't have to be a rocket scientist to know now that Flu is here to stay , and we get a different strain of it each and every year... hence we now have a pattern of pre-planned CHAOS in the NHS due to the planned reduction of Hospital beds by successive Governments. It is not going to get better now ... only worse.

Or is it ?

As it stands NHS bed occupancy is running at 91%

ie. the bed never gets cold


The reason that successive Governments have been able to get away with their planned NHS bed cutting is because the length of stay per patient in hospital has been reduced quite dramatically

''Average length of stay in an NHS hospital has fallen by more than 40 per cent from 8.4 days in 1998/9 to 4.9 days in 2015/16''

You see how the above 40% reduction over 17 years in length of stay (LOS) has almost direct correlation and factors directly into the 50% bed reduction over the last 30 years'

What has helped the hospital patient length of stay to fall so much ?


''Medical innovation, which has enabled less invasive surgery and shortened recovery time, have resulted in reduced length of stay and allowed more people to be treated within existing bed stock. ''

Minimally invasive surgery is associated with less pain, a shorter hospital stay and fewer complications. Laparoscopy — surgery done through one or more small incisions, using small tubes and tiny cameras and surgical instruments — was one of the first types of minimally invasive surgery.Dec 30, 2017

Minimally invasive surgery - Mayo Clinic





When I read the last sentence it makes me confident that the SUN is going to SHINE as what it makes , what it sells , and the services that it plans to offer to the NHS and other Health Services and Private Healthcare providers lies plum in the middle of :


'' less invasive surgery ''


IMO the NHS and others must continue to use '' less invasive surgery '' and the emerging technologies that it uses in order to maximise the bed numbers it now has ... it has no option ... building the number of new Hospitals to make up the shortfall in beds due to an increased population will take YEARS and cost BILLIONS .

Surgical Innovations – Laparoscopic Instruments


Surgical Innovations specialise in the design, development and manufacture of creative solutions for minimally invasive surgery.

An increase in turnover to around 11.25 million pounds and profits to around 1.5 million pounds in the next results will confirm my beliefs.

Also my previous post re M.I.S and Robotics refers.

[gbh2] 13/1/2019 20:55

It's been as late as January 21st so anytime between now and then :)

[jmf69] 13/1/2019 19:54

Trading update tomorrow??

[cashflo] 11/1/2019 22:03

any ideas what the 250k was?

[mandate] 11/1/2019 08:05

Yes, great read, thanks

[bashor] 11/1/2019 07:31

Thanks for that buywell, great breakfast reading, you stop short of saying this share is about to Whoooooooooosh

[bashor] 10/1/2019 20:56

Buywell, your the king of long posts, I’ll stick to the short ones and the hope of retirement very soon

[cashflo] 10/1/2019 20:01

also the ticker code "sun" is also nice I quite like it.

[buywell3] 10/1/2019 19:29

I hate short posts ... working on a bit longer one coming later today

[cashflo] 10/1/2019 19:04

Bashor thanks.

[bashor] 10/1/2019 15:20

Cashflo, I’d like to think the company is in better shape now than at any time in the last few years, the new BOD are of a different breed to the last that seemed to pin profits on royal visits and plan to spend large amounts on flash new premises without the profits to back it up, SUN became debt free in mid 2018 after the fairly large aquasition of Elemental, the weaker pound should be helping sales/profits you would think? At 3p I’d say they should make a good return for you in 2019 assuming BREXIT (there I said it) goes ok, I have a short term personal target of 3.7p but do expect them to go higher in time, good luck

[jmf69] 10/1/2019 15:02

Yep, this should be a big year imo

[bioking] 10/1/2019 15:01

OT) Please look at Futura Medical (FUM) has the BEST ERECTILE DYSFUNCTION DRUG out there wayy better than Viagra which is close to Phase 3 readout .Market cap is only 22 million Drug potential is 1+ BILLION =20++ BAGGER GEM ..


Research Confirms MED2002's US$1 Billion Potential
hxxps://futuramedical.com/content/news/archive17/060317b.asp

The latest market research further endorses Futura's strategy of developing MED2002 as a prescription product in standard and increased strength dose forms, with the objective of switching the standard dose form to an OTC product at an appropriate time.

Ipsos's validated healthcare forecasting model was used to predict peak OTC annual sales for MED2002 in key countries worldwide in excess of US$650 million. This forecast follows earlier market research commissioned into the potential of MED2002 as a prescription product, which indicated a prescription market size of up to US$600 million in key countries worldwide.

Ipsos forecasts that 70% of OTC product sales will be incremental to the prescription ED category. As a result, the estimated peak annual sales of MED2002 in prescription and OTC versions is predicted to be more than US$1 billion prior to the expiry of the product's expected patent life.

The Ipsos valuation was based on the outcomes from primary market research carried out amongst 400 men with ED or suspected ED in the USA. The respondents were in four groups: satisfied users of PDE5 inhibitors (the class of drugs such as Viagra and Cialis); dissatisfied users of PDE5 inhibitors; diagnosed but untreated ED sufferers; and suspected though undiagnosed ED sufferers. The respondents were shown a concept about MED2002 as part of the market research though they did not use the product as it is currently in clinical development.

The key findings of the market research showed that the respondents believed that the product, once approved, is highly differentiated from existing products and that its claims would meet their needs. MED2002's rapid onset of action, an average of less than five minutes, was the key feature that attracted respondents to the product and could command a price premium compared with existing ED treatments, which have a substantially slower onset of action.

The Ipsos healthcare forecasting model has been demonstrated by Ipsos to be within 20% of actual sales volumes in 9 out of 10 of its forecasts.


Pipeline
hxxps://www.futuramedical.com/media/144144/Pipeline-2018.jpg

MED2002 (topical treatment for erectile dysfunction) hxxps://futuramedical.com/content/products/med_2002.asp

first patient dosed: in Q3/Q4 2018
Last patient dosed: by end of June 2019
Headline efficacy results: by end of December 2019

CSD500: Erectogenic condom
hxxps://futuramedical.com/content/products/csd_500.asp

Significant milestone achieved with approval of 2-year shelf life approved for CSD500, the erectogenic condom in September 2018. Development now complete. Discussions are ongoing with current and potential further distribution partners on next steps with the product in a number of markets.

Pain relief products: TPR100 (diclofenac) and TIB200 (ibuprofen) hxxps://futuramedical.com/content/products/tpr_100.asp

TPR100 commercial partner Thornton & Ross filed for UK regulatory submission in July 2018.
Out-licensing discussions for TPR100 outside of the UK are ongoing.

[cashflo] 10/1/2019 14:39

As I am so new to this and I have jumped in already - can any one give me a quick synopsis f the current situation. These are gonna fly yeah?